Cure
Overview
The latest women’s health venture capital news, updated monthly—tracking funding rounds of $5M or more across fertility & reproductive health, menopause & midlife, maternal health, oncology & diagnostics, endometriosis & hormonal conditions, and more.
For more, explore our Biotech Funding and Medtech Funding trackers, updated weekly.
June 2026
Contraline
Date: June 2, 2026 Series: Series B Amount: $92.5M Therapeutic area: Fertility & reproductive health Modality: Hormonal drug (gel) Notable Investors: Co-led by BVF Partners and RA Capital Management; with GV, Lumira Ventures, and Invus
Charlottesville, Virginia–based Contraline raised $92.5M to advance NES/T, an investigational once-daily, reversible hormonal male contraceptive gel, into late-stage (Phase 3) development. The funds support its lead program and additional pipeline assets.
Mammogen
Date: June 10, 2026 Series: Series A Amount: Up to $30M Therapeutic area: Oncology & diagnostics Modality: Blood test / diagnostic Investors: Led by a major U.S. public retirement system
Mammogen raised up to $30M to advance its RNA-powered blood test for earlier breast cancer detection and to reduce unnecessary biopsies.
Clair Health
Date: June 17, 2026 Series: Seed Amount: $11.6M Therapeutic area: Hormonal conditions Modality: Wearable / continuous monitoring Investors: Led by Khosla Ventures; with a16z speedrun, Brydge Club, Treehub, Cartan Capital, Insiders VC, and Anne Wojcicki
Clair Health, founded by two recent Stanford grads, raised $11.6M to build the first noninvasive, continuous hormone monitor for women, tracking estrogen, progesterone, LH, and FSH without blood draws. A consumer launch is planned for late 2026.
May 2026
Oli (Baymatob)
Date: May 26, 2026 Series: Series A3 Amount: $6.5M Therapeutic area: Maternal health Modality: Wearable device Investors: Scale Investors, Clare Ventures, and the University of Sydney
Australia-based Baymatob raised $6.5M to advance Oli, its wireless wearable for predictive maternal and fetal monitoring during labor, ahead of market entry. Oli has raised over $13M in private capital and over $9M in non-dilutive funding to date.
UroMems
Date: May 15, 2026 Series: Series D Amount: $60M Therapeutic area: Other therapeutics Modality: Implantable device Investors: Led by Ajax Health Fund I
French-American UroMems raised $60M, its largest round to date, to advance its smart, automated artificial urinary sphincter implant for stress urinary incontinence, a condition that disproportionately affects women.
April 2026
ONTO Health
Date: April 15, 2026 Series: Series A Amount: $20M Therapeutic area: Fertility & reproductive health Modality: Digital health / AI care Investors: ARTIS and Humania
ONTO Health, led by reproductive endocrinologist Dr. Roohi Jeelani, raised $20M to expand its AI-enabled fertility and longevity care platform across the U.S. and into the Gulf Cooperation Council region. The platform combines evidence-based fertility care with AI diagnostics and clinical automation.
ScreenPoint Medical
Date: April 17, 2026 Series: Growth (existing investors) Amount: $16M ($14M equity + $2M non-dilutive grants) Therapeutic area: Oncology & diagnostics Modality: AI diagnostic software Investors: Insight Partners and Siemens Healthineers
Nijmegen, Netherlands–based ScreenPoint raised $16M to scale its Transpara breast-cancer detection AI, now deployed in 30+ countries with over 12 million mammograms processed.
SimpliFed
Date: April 7, 2026 Series: Series A Amount: $10.8M Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Co-led by Morningside and Hesperia Capital; with Foreground Capital, AHA Social Impact Fund, and Elizabeth Street Ventures
SimpliFed, founded by Andrea Ippolito, raised $10.8M to expand from virtual lactation support into full virtual OB care, serving patients from pregnancy through postpartum in partnership with health systems and clinics.
Osteoboost Health
Date: April 15, 2026 Series: Seed Amount: $8M Therapeutic area: Menopause & midlife Modality: Wearable device Investors: Led by Ambit Health Ventures; with Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures, and Portfolia
Osteoboost Health raised $8M to scale its FDA-cleared wearable that treats low bone density in postmenopausal women with osteopenia through targeted vibration therapy.
Wavelet Medical
Date: April 14, 2026 Series: Seed Amount: $7M Therapeutic area: Maternal health Modality: AI monitoring device Investors: Led by Aegis Ventures
Wavelet Medical raised $7M to bring the first non-invasive, AI-powered fetal brain (EEG) monitoring to labor and delivery, detecting fetal brain distress in real time.
Flora Fertility
Date: April 7, 2026 Series: Seed Amount: $5M Therapeutic area: Fertility & reproductive health Modality: Insurance / fintech Investors: Led by ManchesterStory; with Slauson & Co. and BDC
Flora Fertility raised $5M for individually owned fertility insurance that isn't tied to employment.
March 2026
Nadia Care
Date: March 16, 2026 Series: Growth Amount: $12M Therapeutic area: Maternal health Modality: Care delivery / virtual + community Investors: Led by Valtruis and a national payer; with First Trust Capital Partners and RH Capital
Nadia Care (formerly Cayaba Care) raised $12M to expand its community-centered maternal care model across the U.S. Its model has produced a 60% reduction in NICU days and 38% lower preterm birth rates among members served through regional Medicaid plans.
May Health
Date: March 10, 2026 Series: Growth (existing + new investors) Amount: $11.7M Therapeutic area: Fertility & reproductive health Modality: Medical device Investors: Sofinnova Partners, Trill Impact, Bpifrance, and new investor Nexpring Health
May Health raised $11.7M to advance its Anavi System, a device for PCOS-related infertility, through its U.S. pivotal IDE trial (REBALANCE) and to support European launch planning.
February 2026
Sensei Biotherapeutics / Faeth Therapeutics
Date: February 18, 2026 Series: Acquisition + $200M private placement Amount: ~$200M Therapeutic area: Oncology & diagnostics Modality: Oral therapeutic (M&A) Investors: Private placement co-led by RA Capital Management, Vivo Capital, Cormorant Asset Management, and Fairmount
Sensei Biotherapeutics acquired Faeth Therapeutics alongside a $200M private placement, advancing Faeth's PIKTOR, an oral therapy targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancer.
Midi Health
Date: February 3, 2026 Series: Series D Amount: $100M (at $1B+ valuation) Therapeutic area: Menopause & midlife Modality: Digital health / virtual care Investors: Led by Goodwater Capital; with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, and McKesson Ventures
Midi Health raised $100M, crossing a $1B valuation, to scale its virtual perimenopause and menopause platform across all 50 states, adding OB-GYN, cardiology, and dermatology services.
January 2026
Pomelo Care
Date: January 8, 2026 Series: Series C Amount: $92M (at $1.7B valuation) Therapeutic area: Maternal health Modality: Digital health / virtual care Investors: Led by Stripes; with Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel
Pomelo Care raised $92M to grow its virtual maternity model into broader women's and children's health, including reproductive care, pediatrics, and menopause. The company now covers more than 25 million lives.
Pee Safe
Date: January 2026 Series: Series C Amount: $32M Therapeutic area: Other therapeutics Modality: Consumer health Investors: Led by OrbiMed; with Alkemi Growth Capital
Pee Safe raised $32M to scale its period, feminine, and intimate-hygiene and personal-care business, expanding into 23 international markets.
BrightHeart
Date: January 8, 2026 Series: Series A Amount: $12.6M Therapeutic area: Maternal health (prenatal diagnostics) Modality: AI diagnostic software Investors: Co-led by Odyssée Venture and GO Capital; with Sofinnova Partners and the Mussallem CHD Alliance
BrightHeart (France/U.S.) raised over $12M to scale its FDA-cleared AI platform for prenatal ultrasound, which improves congenital heart defect detection to over 96%. Funds support U.S. commercialization and European expansion.
Science&Humans
Date: January 2026 Series: Series A Amount: $7M Therapeutic area: Endometriosis & hormonal conditions Modality: Digital health / telehealth platform Investors: Led by Pender Ventures; with WELL Health Technologies, CIBC Innovation Banking, and Michele Romanow
Toronto-based Science&Humans raised $7M to scale its hormone-health platform across Canada, treating PCOS, PMS, PMDD, endometriosis, perimenopause, and menopause.
ShanX Medtech
Date: January 14, 2026 Series: Seed Amount: $28M Therapeutic area: Oncology & diagnostics Modality: Diagnostic device Investors: Borski Fund, NextGen Ventures, CbusineZ, BOM, and Invest-NL
Netherlands-based ShanX Medtech raised $28M for its ultra-rapid antimicrobial susceptibility testing platform, initially focused on UTIs, which disproportionately affect women.
Feminai
Date: January 12, 2026 Series: Seed Amount: $6M Therapeutic area: Oncology & diagnostics Modality: Wearable / AI Investors: Led by Vertex Ventures Israel; with ICI Fund, Fusion VC, Arben Ventures, and Cactus Capital
Israel-based Feminai raised $6M to develop its AI-powered wearable for at-home breast cancer screening.
